(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 34.84% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 122.56%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.21%.
Harrow's revenue in 2025 is $227,661,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2025 to be $10,629,973,630, with the lowest HROW revenue forecast at $10,012,037,959, and the highest HROW revenue forecast at $11,247,909,301. On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $15,011,766,575, with the lowest HROW revenue forecast at $13,166,840,074, and the highest HROW revenue forecast at $17,533,092,122.
In 2027, HROW is forecast to generate $20,965,780,279 in revenue, with the lowest revenue forecast at $17,993,398,694 and the highest revenue forecast at $24,185,336,132.